Capricor Therapeutics (NASDAQ:CAPR) Cut to Strong Sell at Wall Street Zen

Wall Street Zen lowered shares of Capricor Therapeutics (NASDAQ:CAPR) from a sell rating to a strong sell rating in a research note published on Saturday.

A number of other equities analysts have also recently commented on CAPR. Alliance Global Partners cut shares of Capricor Therapeutics from a “buy” rating to a “neutral” rating and set a $7.00 price objective for the company. in a research report on Tuesday, July 28th. Cantor Fitzgerald cut shares of Capricor Therapeutics from an “overweight” rating to a “neutral” rating and set a $3.50 target price for the company. in a research note on Thursday, July 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Monday, June 15th. Maxim Group lowered shares of Capricor Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. Finally, HC Wainwright reissued a “neutral” rating on shares of Capricor Therapeutics in a report on Monday, July 27th. Ten analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus price target of $29.15.

Capricor Therapeutics Stock Performance

Shares of NASDAQ:CAPR opened at $4.20 on Friday. Capricor Therapeutics has a 52-week low of $2.96 and a 52-week high of $40.37. The company has a market capitalization of $243.22 million, a P/E ratio of -1.81 and a beta of 0.54. The company has a 50-day simple moving average of $22.51 and a 200 day simple moving average of $26.64.

Capricor Therapeutics (NASDAQ:CAPR) last released its quarterly earnings data on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.04). As a group, equities analysts forecast that Capricor Therapeutics will post -1.62 earnings per share for the current year.

Insider Transactions at Capricor Therapeutics

In other Capricor Therapeutics news, CFO Anthony Bergmann sold 24,100 shares of the business’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $30.38, for a total value of $732,158.00. Following the completion of the sale, the chief financial officer owned 11,223 shares of the company’s stock, valued at $340,954.74. The trade was a 68.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Over the last ninety days, insiders have sold 25,000 shares of company stock valued at $759,158. Insiders own 9.20% of the company’s stock.

Institutional Investors Weigh In On Capricor Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in Capricor Therapeutics by 16.1% in the 4th quarter. Vanguard Group Inc. now owns 2,561,880 shares of the biotechnology company’s stock valued at $73,936,000 after acquiring an additional 355,161 shares in the last quarter. Suvretta Capital Management LLC bought a new position in shares of Capricor Therapeutics in the fourth quarter worth $51,533,000. Tang Capital Management LLC bought a new position in shares of Capricor Therapeutics in the fourth quarter worth $49,062,000. RA Capital Management L.P. acquired a new position in Capricor Therapeutics in the fourth quarter valued at about $43,516,000. Finally, Geode Capital Management LLC raised its stake in Capricor Therapeutics by 5.8% in the fourth quarter. Geode Capital Management LLC now owns 1,017,332 shares of the biotechnology company’s stock valued at $29,367,000 after purchasing an additional 55,766 shares in the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics News Summary

Here are the key news stories impacting Capricor Therapeutics this week:

• Negative Sentiment: FDA staff and panel members reportedly questioned whether clinical data adequately demonstrated deramiocel’s effectiveness, creating uncertainty around the therapy’s regulatory prospects and Capricor’s valuation. StockWatch: Capricor Plunges as FDA Panel, Staff Question Effectiveness of Lead Candidate Deramiocel
• Negative Sentiment: Several law firms announced or promoted securities-fraud investigations and class actions alleging that Capricor and certain executives made materially misleading statements about clinical data. The lawsuits cover investors who purchased shares from December 17, 2025, through July 26, 2026, and cite a stock decline of approximately 64%. The allegations have not been proven. CAPR Investors Have Opportunity to Lead Capricor Therapeutics Securities Fraud Lawsuit
• Negative Sentiment: The wave of litigation-related notices adds legal, financial and reputational risk and may weigh on investor sentiment. Eligible shareholders generally have until September 28, 2026, to seek appointment as lead plaintiff; the deadline does not itself determine the merits of the case. Kaplan Fox Alerts Capricor Investors to Securities Class Action Deadline
• Neutral Sentiment: JonesTrading downgraded its stance on Capricor to “Hold,” reflecting a more cautious view following the regulatory concerns and sharp share-price decline. Capricor Therapeutics Cut to Hold at JonesTrading

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.